Physician
Obstetrics & Gynecology
Dr. Gordon B. Mills, MD
|
|
Give Review
Gordon Mills works in the field of Obstetrics & Gynecology. Gordon Mills is a published physician. He published 101 publications, including: 'Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.'
Publications
- Reply to M.P. Decatris et al.
- Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival.
- New era of integrated cancer biomarker discovery using reverse-phase protein arrays.
- Large-Scale Drug Screens Support Precision Medicine.
- Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines.
- mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer.
- A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of t...
- MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer.
- TransVar: a multilevel variant annotator for precision genomics.
- PKCiota promotes ovarian tumor progression through deregulation of cyclin E.
- Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
- Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
- Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors.
- Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer.
- Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.
- Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.
- Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
- Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks.
- α-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration.
- Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers.
- Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.
- Development of a robust classifier for quality control of reverse-phase protein arrays.
- Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and Oxidative Phosphorylation in melanoma.
- P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors.
- Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma.
- A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer.
- RADical Response Puts an Exceptional Responder in CHKmate: A Synthetic Lethal Curative Response to DNA-Damaging Chemotherapy?
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer.
- Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF.
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma.
- Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis.
- Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors.
- Definition of PKC-α, CDK6 and MET as therapeutic targets in triple-negative breast cancer.
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types.
- Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation.
- Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer.
- Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
- Realizing the promise of reverse phase protein arrays for clinical, translational and basic research : a workshop report.
- Unraveling the regulatory connections between two controllers of breast cancer cell fate.
- A curated census of autophagy-modulating proteins and small molecules: Candidate targets for cancer therapy.
- Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein.
- Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
- Concordance of Genomic Alterations Between Primary and Recurrent Breast Cancer.
- Cancer Systems Biology: a peek into the future of patient care?
- Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by ...
- Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.
- Genome-wide transcriptome profiling of homologous recombination DNA repair.
- Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer.
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
- Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.
- Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.
- Bias from removing read duplication in ultra-deep sequencing experiments.
- Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes.
- Perturbation biology: inferring signaling networks in cellular systems.
- Modeling precision treatment of breast cancer.
- PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells.
- The Somatic Genomic Landscape of Glioblastoma.
- Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
- The Cancer Genome Atlas Pan-Cancer analysis project.
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts.
- TCPA: a resource for cancer functional proteomics data.
- A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
- Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
- Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules.
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers.
- Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8.
- Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer.
- AMPK: A Contextual Oncogene or Tumor Suppressor?
- Building a personalized medicine infrastructure at a major cancer center.
- Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.
- EVI1 splice variants modulate functional responses in ovarian cancer cells.
- TARDBP regulates glycolysis in hepatocellular carcinomaby regulating PFKP through miR-520.
- Mask Is Required for the Activity of the Hippo Pathway Effector Yki/YAP.
- Site-specific activation of AKT protects cells from death induced by glucose deprivation.
- BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- Repurposing the Pap smear: one step closer to gynecologic cancer screening.
- Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.
- The impact of tumor heterogeneity on patient treatment decisions.
- Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals.
- High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.
- Rab25 in cancer: a brief update.
- Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
- Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
- Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents.
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer.
- Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy.
- Overcoming implementation challenges of personalized cancer therapy.
- Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells.
- Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation ...
- AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis.
- Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis.
- cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes.
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
- Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Similar Doctors
|
Dr. Joyce H. Holz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael W. Bevers, MD |
|
|
Dr. Kathleen M. Schmeler, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Michael D. Hold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Gershenson, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. John M. Alaniz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael M. Frumovitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter V. Weston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary J. Zanders, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noelle R. Niemand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Lu, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jubilee Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Liz Y. Han, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Barr Sr., MD |
|
|
Dr. Jennifer E. Dietrich, MD
This Doctor is OpenDoctor Recommended.
|